NOTCH1 and acute lymphoblastic leukemia: The frequent identification of gain-of-function mutations in NOTCH1 in T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) prompted the rapid development of the first clinical trial of Merck‘s GSI drug MK-0752 in patients with relapsed/refractory T-ALL [134].